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Abstract
Hydrogen peroxide (H2O2) is involved in various signal transduction pathways and cell fate decisions. The mechanism
of the so called “redox signaling” includes the H2O2-mediated reversible oxidation of redox sensitive cysteine residues
in enzymes and transcription factors thereby altering their activities. Depending on its intracellular concentration and
localization, H2O2 exhibits either pro- or anti-apoptotic activities. In comparison to normal cells, cancer cells
are characterized by an increased H2O2 production rate and an impaired redox balance thereby affecting the
microenvironment as well as the anti-tumoral immune response. This article reviews the current knowledge
about the intracellular production of H2O2 along with redox signaling pathways mediating either the growth
or apoptosis of tumor cells. In addition it will be discussed how the targeting of H2O2-linked sources and/or
signaling components involved in tumor progression and survival might lead to novel therapeutic targets.
Introduction
Hydrogen peroxide (H2O2) is next to the superoxide
anion and hydroxyl radical a key member of the class of
reactive oxygen species (ROS), which are in particular
generated via the respiratory chain cascade but also as
byproducts of the cellular metabolism including protein
folding. In contrast to the superoxide anion and
hydroxyl radical, the less reactive H2O2 is involved in
many physiological processes such as hypoxic signal
transduction, cell differentiation and proliferation but
also plays a role in mediating immune responses. How-
ever, it exerts its effects depending on the cellular con-
text, its local concentration as well as its exposure time
[1, 2]. Thus H2O2 is no more considered as an unwanted
rather toxic byproduct, but plays an important role in
the control of vital cellular processes.
Tumor cells are characterized by an enhanced meta-
bolic activity resulting in changes of the cellular redox
state that has to handle the production of high levels of
ROS [3]. In many cancer cells persistently upregulated
H2O2-dependent signaling pathways are involved in cell
differentiation, growth and survival, yet high levels of
H2O2 can also induce cell cycle arrest or apoptosis in
cells. Due to this dual functionality of H2O2 robust
cellular anti-oxidative systems are thought to be essen-
tial for maintaining the cellular redox homeostasis.
Several defense systems against oxidative stress have
been shown to be upregulated in cancer cells via the
transcription factor nuclear factor-erythroid 2 p45-related
factor 2 (Nrf2) [4]. These include the thioredoxin/thiore-
doxin reductase (Trx/TrxR) system, peroxiredoxins (Prxs)
and several glutathione S-transferases (GSTs), which are
involved in mediating the cellular redox homeostasis, but
still allow redox modifications of specific redox-sensitive
proteins thereby triggering redox signaling events. In this
review we will address how (i) cellular H2O2 is produced
and how it regulates certain signaling pathways, (ii) tumor
cells cope with enhanced H2O2 levels to escape from oxi-
dative stress, (iii) potential redox-sensors might be corre-
lated with tumorigenesis, and how (iv) H2O2-modulated
processes/pathways might be used as therapeutic targets.
Sources of H2O2
Reactive oxygen species (ROS) represent a class of
oxygen-containing chemical compounds that are defined
by their reactivity towards biological targets, including
lipids, proteins and DNA [3]. The most prominent
member of this class is the superoxide anion (O2
−),
largely produced by either the mitochondrial electron
transport chain, in particular its complexes I, II and III,
or by NAD(P)H oxidases (NOXs). The O2
− is rapidly
converted to H2O2 by distinct superoxide dismutases
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(SODs) (Fig. 1) or to hydroxyl radicals (OH●) [5]. While
O2
− released into the mitochondrial matrix is directly
converted by SOD2 into the less reactive H2O2, O2
− re-
leased by the complex III into the mitochondrial inter-
membrane space can be exported via voltage-dependent
anion channels (VDAC) into the cytosol followed by a
SOD1-mediated conversion into H2O2 [6, 7]. In
addition, cellular membrane-associated NOXs transfer-
ring electrons from NAD(P)H across cell membranes to
molecular oxygen (O2) are producers of superoxide an-
ions. Via NOX2 O2
− can be transported into the extracel-
lular space, where it can be either converted to H2O2 by
SOD3 or re-imported via chloride channels [8]. Given
that SODs are characterized as highly efficient enzymes
the intracellular (cytosol - SOD1, mitochondria - SOD2)
and extracellular (SOD3) balance is shifted towards the
formation of H2O2, which diffuses relatively free or is
receptor-mediated transported across biological mem-
branes [9] thereby acting as an intra- and intercellular
signaling molecule (Fig. 1). In contrast, the hydroxyl rad-
ical (OH●) is considered as the most reactive ROS
species. Due to its high reactivity towards lipids, proteins
and DNA, it has a short half-life thereby limiting its
diffusion but causing damage largely at its site of
production.
Transport and subcellular localization of hydrogen
peroxide
In comparison to water, H2O2 possesses a reduced mem-
brane permeability, which is influenced by the phosphor-
ylation and glycosylation states of membrane proteins,
the lipid composition (lipid rafts) and osmotic stretching
of lipid bilayers [10–16]. Aquaporin (AQP) 8, but not
the classical AQP1 facilitates the transport of H2O2
across membranes [17, 18]. Treatment of AQP3-
overexpressing HeLa cells with H2O2 resulted in an
enhanced phosphorylation of protein kinase B (AKT)
[19], while overexpression of AQP8 increased intracellu-
lar H2O2 levels in leukemia cells in the presence of
H2O2. Moreover, vascular endothelial growth factor
(VEGF) signaling results in increased intracellular H2O2
levels, which can be reduced by silencing AQP8 [20].
Furthermore, silencing of AQP8 can inhibit the epider-
mal growth factor (EGF) mediated stimulation of
tyrosine kinases. [21]. Thus, AQPs not only play import-
ant roles in the diffusion of H2O2 across membranes,
Fig. 1 Interplay between physiological/pathophysiological H2O2 generation and the anti-oxidative response mechanism. a H2O2 is produced, e.g. in response
to growth factors by the NOX/SOD system and enters cells through simple diffusion and facilitated diffusion through AQPs, respectively, leading to increased
intracellular H2O2 levels. b Peroxiredoxins (Prx) act as highly active redox sensors and are part of one of the main H2O2 detoxifying systems. Hyperoxidation
inactivates Prxs allowing c the oxidation of sensitive cysteine residues in cellular proteins including transcription factors. d The Nrf2 system is activated
in response to increased H2O2 levels leading to the anti-oxidative response. AQP, aquaporin; GF, growth factor; GFR, growth factor receptor.
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but also on downstream signaling cascades. Further-
more, H2O2 detoxifying enzymes, such as glutathione
peroxidases (GPxs), catalases and Prxs, can lead to rap-
idly decreasing intracellular H2O2 concentrations [9]
thereby establishing the formation of H2O2 gradients
resulting in selective and localized H2O2 signaling
events. The inactivation of scavenger enzymes by H2O2
represents a mechanism that allows the selective enrich-
ment (“flooding”) of a cellular area by H2O2 thereby
promoting the H2O2-mediated oxidation of specific
thiols within target proteins at this site [22, 23].
Features of H2O2 – second messenger like
characteristics and principles of redox modifications
Since H2O2 is produced, enzymatically removed and
exerts a low overall reactivity, but a relatively high se-
lectivity towards certain proteins, in particular proteins
containing thiol groups [24, 25], it is postulated to act as
a second messenger. H2O2 mediates chemical modifica-
tions of specific cysteine residues, which are overrepre-
sented in functionally relevant regions of some proteins
[26]. Approximately 10 % of free cysteines are ionized at
pH 7.4 due to their low pKa and thus are more suscep-
tible to H2O2 than protonated cysteine thiol groups [27].
Although H2O2 detoxification enzymes, like GPxs, Prxs
and catalase, are more abundantly expressed than pro-
teins involved in the redox signaling [28], cysteine resi-
dues of the ubiquitously expressed Prxs are prone to be
oxidized at even relatively low H2O2 levels [29–31]. In
contrast, signaling molecules e.g. protein tyrosine phos-
phatases (PTPs) require extremely high concentrations
of H2O2 to undergo oxidation [9]. Furthermore, if Prxs
are inactivated by over-oxidation or phosphorylation this
might lead to localized H2O2 accumulation thereby trig-
gering redox signaling [22] (Fig. 1). The first step of oxi-
dative thiol/thiolate modification by H2O2 is the
formation of sulfonate or sulfenic acid (R-SOH), which
might reacts with any thiol in the vicinity, e.g. glutathi-
one (GSH) to form inter- and intramolecular disulfide
bonds or protein-SSGs, respectively. In some cases, e.g.
with electron-rich amino groups they also form sulfeny-
lamides (Fig. 2). These oxidized forms can be easily re-
duced to thiolate by the Trx- and GSH-based anti-
oxidative systems thereby ensuring the reversibility of
redox modifications caused by H2O2. In the presence of
excessive concentrations of H2O2 further oxidation of
sulfenic acids might occur thereby resulting in the for-
mation of sulfinic (−SO2H), sulfonic acids (−SO3H) or
their respective anions. In general these sulfur (IV) and
(VI) oxidative states are irreversible oxidation products
and some of these species can be linked to H2O2-medi-
ated toxicity (Fig. 2). However, if these oxidative modifi-
cations occur in members of the Prx family their
reduction can be mediated by sulfiredoxins (Srx) [32],
which might represent an adaptive process of eukaryotic
cells to cope with increased H2O2 levels [22, 23].
Fig. 2 Redox modifications of reactive cysteine residues by H2O2. Redox-sensitive proteins contain cysteine residues, which are partially ionized under
physiological pH. Oxidation of this thiolate anion (1) results in a sulfenic acid or rather its salt (2), which is relatively reactive and forms intra-/intermolecular
disulfide bonds in the presence of thiolate. This sulfenylation can be intramolecular or intermolecular (3), the latter predominantly with GSH to form
glutathionylated intermediates (5), or sulfenylamides with oxidizable amines (4) and glutathionylated intermediates (5), respectively. These
redox modifications result in altered functions of their target proteins and can be reversed by the Trx- or GSH-based anti-oxidative systems. Under excessive
H2O2 concentration the sulfonate or sulfonamide intermediates can be further irreversibly oxidized to sulfinic (6) and sulfonic acids (7) forming the respective
anions under physiological pH thus also shifting the isoelectric points of affected proteins.
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The anti-oxidative response – factors that maintain
redox signaling
Whereas intracellular O2
− concentrations are tightly con-
trolled by the activity of SODs and thus kept at very low
levels [33], the metabolite H2O2 is a rather stable ROS
compound. Cells have developed distinct mechanisms to
maintain the production and clearance of such reactive
species in a homeostatic state in order to properly proliferate
and to differentiate. Tumor cells are metabolically hyper-
active resulting in the production of excessive ROS levels in-
cluding H2O2. To cope with enhanced H2O2 concentrations
and to protect cells from oxidative damage, anti-oxidative
defense systems are upregulated, which results in a shift of
the redox balance towards an upregulation of pro-survival
signaling pathways as summarized in Table 1 for a set of
Nrf2-regulated anti-oxidative proteins and their correlation
to cancer.
Transcription factor Nrf2 as regulator of the anti-oxidative
response
Nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) is a
transcription factor (TF) that plays a key role in controlling
the response to oxidative stress by its regulation of anti-
oxidative enzymes, phase II enzymes and enzymes of the
glutathione biosynthesis. Under physiological conditions
the constitutive abundance of active Nrf2 is relatively low
due to its continuous proteasomal degradation, but can be
modified at the post-translational level to ensure rapid and
efficient adaption to metabolic alterations in particular to
oxidative stress. The best characterized repressor of Nrf2 is
the kelch-like ECH-associated protein (Keap1), which
serves as a substrate adapter protein within the RBX1 E3
ubiquitin ligase complex (CRLKeap1) [34]. Keap1 contains
multiple highly reactive cysteine residues, which can act as
stress sensors, if modified by electrophiles or oxidants, e.g.
from food [35]. This results in an altered conformation of
Keap1 and an impaired binding capacity to Nrf2 thereby
preventing Nrf2 from proteasomal degradation. Thus, Nrf2
accumulates in the nucleus leading to the induction of
genes by binding to the anti-oxidant response element
(ARE) in their promoter regions (Fig. 3). In addition Nrf2
undergoes post-translational modifications such as PKC-
dependent phosphorylation on Ser-40, phosphorylation
through the MAPK/ERK signaling pathways in response to
endoplasmic reticulum/unfolded protein stress or by casein
kinase and CBP/p300 also promoting its binding to such
ARE sites. The activation of Nrf2 can be also mediated by
additional signal transduction pathways, e.g. ERK, c-Jun
amino-terminal kinase (JNK), AMP-activated protein kin-
ase (AMPK) or PI3K/AKT promoting anti-oxidative ef-
fects, which mediate enhanced resistance to oxidative
stress as well as to further oxidative insults [36–38]. Con-
stitutive stabilization of Nrf2 is found in several human
cancers [39–41] and is associated with increased cancer
chemotherapy resistance, enhanced tumor progression
[42, 43] and poor prognosis and/or survival for patients
[40, 44, 45]. Mechanisms by which the Nrf2 signaling
pathway is constitutively activated in several types of can-
cer include (i) somatic mutations of Keap1 disrupting the
binding capacity to Nrf2, (ii) epigenetic silencing of Keap1
and (iii) transcriptional induction of Nrf2 by oncogenes
such as K-ras, B-raf or c-myc [46] (Fig. 3). Furthermore,
increased levels of ROS (H2O2) and increased Nrf2 activity
in tumor cells, result in an enhanced anaerobic glycolysis
and utilization of the pentose phosphate pathway activity
to generate NAD(P)H equivalents necessary for the Trx-
and GSH-based anti-oxidative systems [47]. Since
NAD(P)H generating enzymes are Nrf2 targets, the energy
metabolism is directly connected with the redox homeo-
stasis (Fig. 4). This is confirmed by an increased metabolic
oxidative stress and cytotoxicity in response to the inhib-
ition of glycolysis and/or the pentose phosphate pathways
in combination with an inhibition of the Trx metabolism
[48]. In contrast, knock down of Nrf2 suppresses tumor
growth, inhibits cell proliferation and promotes increased
apoptosis [44, 49]. The fact, that several cancers exhibit
induced Nrf2 levels associated with enhanced tumor pro-
gression and chemotherapy resistance, whereas the lack of
Nrf2 has opposite effects, Nrf2 represents a promising tar-
get for cancer therapies.
Table 1 Nrf2 targets and their correlation to cancer
target name relation to cancer
Trx1 thioredoxin 1 proto-oncogene expressed in many cancers
[224]
elevated serum levels in patients with ovarian
cancer [225]
overexpression in HCC, CRC, liver metastasis
[224] and
in breast cancer [226]
TrxR1 thioredoxin
reductase1
overexpressed in many cancer cells and cell
lines of distinct histology [227]
TXNIP thioredoxin
interacting protein
negatively interferes with bladder
carcinogenesis [228]
tumor suppressor in thyroid cancer [229]
Prx1 peroxiredoxin 1 increased expression in pancreatic cancer
[230], breast cancer [226, 231] and HCC [232]
promotion of lung cancer progression [233]
related to tumor angiogenesis in pancreatic
cancer [230]
Prx6 peroxiredoxin 6 promotion of lung tumor growth [234, 235]
repressed expression in papillary thyroid
carcinomas [236]
Srx sulfiredoxin oncogenic role in skin tumorigenesis [237]
overexpression in squamous cell carcinoma
[56]
promotion of lung cancer progression [69]
CRC colorectal carcinoma, HCC hepatic cell carcinoma
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Targets of Nrf2
Peroxiredoxins
Prxs represent members of the so called thiol-based anti-
oxidant system [50] that act as redox switches to modulate
homeostasis [51]. As important H2O2 scavenging enzymes
Prxs are involved in the anti-oxidative response and in the
regulation of redox-dependent signaling pathways by con-
verting H2O2 into water [52, 53]. In mammals, the family
of Prxs consists of 6 members located either in the cytosol
(Prx1, Prx2, Prx4, Prx5, Prx6), mitochondria (Prx3, Prx5)
or in other cellular compartments (Prx1, nucleus; Prx2,
membrane; Prx4, Golgi apparatus, extracellular space,
endoplasmic reticulum; Prx5, peroxisomes) [9, 54]. Prxs are
upregulated under conditions of oxidative stress [55–57]
and it could be shown that Prx1 and Prx6 are direct targets
of Nrf2 [58, 59]. Prx1 – Prx5 are 2-Cys-Prx and utilize Trx
as electron donor for their catalytic activity, while Prx6 is a
1-Cys-Prx and depends on GSH instead of Trx for its re-
duction [54, 60]. The hyper-oxidation of 2-Cys Prx, in par-
ticular of Prx1, adds further chaperone function to these
Prxs, but depends on certain motif elements downstream
of the peroxidatic cysteine residue (GGLG and YF motifs)
[23, 61]. The chaperone function is based on the formation
of stack like higher molecular weight complexes, thereby
preventing the denaturation of proteins from external
stresses like heat shock or oxidative stress. This multimeric
complex can be subsequently dissolved into low molecular
weight species by Srx [61]. Whereas in some species more
distant cysteine residues might act as redox sensors, human
Prxs are known to gain such a chaperone function only
after the peroxidatic cysteine is hyper-oxidized [51]. At the
transcriptional level Nrf2 and to some degree also focal ad-
hesion kinase (FAK) have been demonstrated to activate
the expression of Prxs [62, 63]. However, there is also evi-
dence that modifications at the post-translational level have
an impact on the function of Prxs. For example nitrosyla-
tion of the tyrosine residue within the YF motif of Prx2
plays a crucial role in the regulation of disulfide bond for-
mation under oxidative stress conditions resulting in a
more active and robust peroxidase [64]. In addition, its glu-
tathionylation may affect its localization to the extracellular
compartment, along with Trx, thereby inducing TNFα
Fig. 3 The Nrf2/Keap1 signaling pathway. Under basal conditions Nrf2 is bound by two molecules of Keap1, poly-ubiquitinylated by the Cul3 system and
thereby marked for proteasomal degradation. Only a small portion of Nrf2 escapes from this degradation process and translocates to the nucleus to
maintain the basal expression of anti-oxidant response genes. Under stress conditions like elevated levels of H2O2 Keap1 is modified at redox sensitive
cysteine residues leading to an impaired conformation and inactivation of Keap1. Newly translated Nrf2 escapes ubiquitinylation, translocates to the
nucleus and induces the anti-oxidative stress response. Mechanisms for the continuously accumulation of Nrf2 in the nucleus of several cancer cells can be
triggered by (i) mutations of Keap1 associated with its inactivation, (ii) epigenetic silencing of Keap1 and (iii) mutations of oncogenes such as K-ras, B-raf
and c-myc leading to the transcriptional induction of Nrf2.
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production leading to an oxidative stress-dependent in-
flammatory reaction [65]. For Prx3 the complex formation
of FoxO3a with the peroxisome proliferator-activated
receptor-gamma coactivator 1 alpha (PGC1 alpha) is en-
hanced by sirtuin-1 (SirT1), which is similar to the regula-
tion of other anti-oxidant proteins [66]. The Prx4, which
is mainly expressed in the endoplasmic reticulum com-
partment can be enhanced at the post-transcriptional level
by calpain [67]. Due to its high susceptibility to undergo
hyperoxidation even at low levels of oxidative stress its
chaperone function is frequently involved in the oxidative
folding of various ER resident proteins, likely in cooper-
ation with protein disulfide isomerase (PDI) [68]. There is
also evidence that Prx4 in addition to Srx plays a crucial
role in enhancing RAS-RAF-MEK signaling to control
cancer cell proliferation and metastasis formation [69].
Sulfiredoxins
Srxs reduce double oxidized catalytic cysteine (sulfinic
acid) residues of 2-Cys-Prxs [70] thereby restoring their
peroxidase function [32, 71]. Based on studies in yeast,
the rate constant for the reduction of oxidized Prx by
Trx (about 106 M−1 s−1) is much faster than the rate of
reduction of hyperoxidized Prx by Srx [72, 73]. Thus,
the reduction of hyperoxidized Prx by Srx might be con-
sidered as a rate limiting step. Moreover Srxs are in-
volved in deglutathionylation processes [74] and can
regulate the chaperone function of Prx1 by controlling
its glutathionylation levels at position cysteine 83 [75].
In contrast to its anti-oxidant function, which is highly
specific for Prxs, the deglutathionylation activity of Srx
appears much less restricted [51]. The Srx promoter
contains a sequence resembling the consensus sequence
for ARE, which is important for its regulation [76]. In
response to cigarette smoke and under hypoxic condi-
tions, Srx expression is transcriptionally controlled in a
Nrf2-dependent manner [77, 78]. By using overexpres-
sion and knock out model systems it has been demon-
strated that upon treatment with the chemopreventive
Nrf2 inducer 3H-1,2-dithiole-3-thione (D3T) the expres-
sion of Srx is upregulated and thus prevents the double
oxidation of Prx in neurons [79]. Moreover, hyperoxia
has been shown to induce the degradation of mitochon-
drial double oxidized Prx3 in Nrf2-deficient, but not in
WT mice. Thus, in the absence of Srx hyperoxidized Prx
becomes susceptible to proteolysis [78]. In addition, the
disparate resistance of colon carcinoma cells to ROS has
been linked to higher basal levels of Nrf2 and Srx as well
as to their distinct cellular localizations [56, 80].
Thioredoxin / thioredoxin reductase / TXNIP system
Trxs are small ubiquitously expressed proteins maintain-
ing the cellular environment in a reduced state [81].
Trxs are involved in the catalysis of redox-dependent re-
actions, display oxidoreductase activity, serve as electron
donors for enzymes with biosynthetic properties [82]
Fig. 4 Maintenance of redox homeostasis by Nrf2. Nrf2 induces the expression of genes coding for enzymes involved in (a) hydrogen peroxide
detoxification and (b) redox signaling. (c) High levels of H2O2 activate Nrf2 resulting in the induction of the anti-oxidative stress response. The red
boxes symbolize Nrf2 inducible enzymes
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and are involved in the transcriptional control of diverse
physiologic and pathophysiologic processes such as cell
growth [83], proliferation [84], apoptosis [85] and in-
flammation [86]. Under physiological conditions Trx is
fully reduced and interacts with pro-apoptotic proteins,
such as apoptosis signaling kinase 1 (ASK1), the tumor
suppressor phosphatase and tensin homologue deleted
on chromosome 10 (PTEN), activator protein 1 (AP-1)
and p53 [87–89]. In general reversible oxidized redox
sensitive cysteine residues of proteins are largely
dependent on Trx, which restores their reduced state.
However, the enzymatic activity of Trxs relies on the ac-
tivity of thioredoxin reductases (TrxR), which are seleno-
proteins and reduce oxidized Trxs under consumption of
NAD(P)H [90–93]. Thus, at least baseline activities of
TrxR are necessary for cell survival (Fig. 5). As a conse-
quence TrxR might serve as a potential target for cancer
treatment by its targeting with electrophilic compounds,
which might interact with the redox-active moiety of TrxR
[94]. In contrast, the thioredoxin interacting protein
(TXNIP) inhibits Trx by binding to its catalytic site
thereby competing with other proteins such as ASK1
resulting in an increased susceptibility to undergo apop-
tosis. In addition, low TXNIP expression correlates with
an enhanced tumorigenicity [95] and increased metastasis
formation [96].
Glutathione system
The glutathione (GSH) system is a major thiol-based
defense system against oxidative and electrophilic stress in
mammals and functions as co-substrate for the GPxs,
which efficiently remove H2O2 thereby preventing oxidative
insults and influencing together with glutaredoxin (Grx)
the redox state of proteins via reversible S-glutathionylation
[97]. Thus GSH plays an important role in redox-signaling
and in the regulation of protein functions. In addition key
enzymes of the GSH biosynthesis can be upregulated by
Nrf2 [98].
The specific role of H2O2 in cancer
Whereas low ROS levels seem to be relevant for the
maintenance of cellular homeostasis in normal cells,
most cancer cells show metabolic alterations resulting in
significantly higher ROS levels, which can trigger either
pro- as well as anti-tumorigenic processes. The in-
creased levels of ROS can promote pro-survival and
pro-proliferative pathways as well as the metabolic adap-
tion of tumor cells to the tumor environment [99]. The
latter includes phosphatidylinositol 3-kinase (PI3K)/
AKT/mammalian target of rapamycin (mTOR) resulting
at least in part in an increased mitochondrial metabol-
ism [100] along with the inhibition of the anti-oxidative
response by phosphorylating members of the fork head
box O transcription factor (FOXO) family [101, 102], of
the mitogen-activated kinase (MAPK/ERK) as well as of
the hypoxia-inducible factor (HIF) signaling cascades
[103–105]. Moreover, several oncogenes linked to these
pathways, such as RAS, MYC and AKT as well as muta-
tions or loss of tumor suppressors like p53, are associ-
ated with increased ROS levels [106, 107]. Yet, increased
spatially localized ROS levels can also promote cell tox-
icity thereby leading to the activation of cell cycle arrest
or cell death-inducing pathways resulting in the inhib-
ition of cancer progression [108, 109]. Thus cancer cells
do not only have to cope with higher ROS levels [110, 111],
but also have to maintain their redox balance, which is fre-
quently accomplished by up-regulating anti-oxidants [112].
In addition, the master regulator of the cellular anti-oxidant
response Nrf2 can be activated and stabilized by a number
of oncogenes, for example PI3K, K-ras or MYC [47, 113],
known to drive signaling cascades that mediate cancer cell
proliferation and/or survival. Furthermore, primary tumor
cells exert not only higher expression levels of ROS scaven-
gers, including Prxs, SODs and GPxs, but also structural al-
terations of the Nrf2 inhibitor Keap1 suggesting that an
imbalanced redox status promotes tumorigenicity [114–116]
(Fig. 6). This is in accordance with an enhanced tumor pro-
gression rate in response to treatment with anti-oxidants
[117] and an increased resistance to chemotherapeutic drugs
via the activation of the Nrf2 [118]. In this context it is note-
worthy that several hallmarks of cancer can be directly
Fig. 5 Trx-based upregulation of anti-oxidative systems by Nrf2. Oxidized
Trxs are reduced by TrxRs and maintained in their active form. Reduced
Trxs can reduce oxidized Prxs, which under physiological conditions
detoxify H2O2. Reduced Trxs can interact with redox-sensitive proteins,
such as ASK1, PTEN, AP-1 and p53 suggesting that different cellular
processes such as proliferation, the cellular metabolism and apoptosis
and might be regulated by Trxs.
Lennicke et al. Cell Communication and Signaling  (2015) 13:39 Page 7 of 19
linked to an increased ROS production [119], such as sus-
tained proliferative signaling [99], resistance to cell death
[120], activation of invasion and metastasis [121] as well as
induction of angiogenesis [122]. The role of H2O2 as a
promoter of neoplastic transformation is supported by the
modulation of the PI3K/AKT signaling pathway due to oxi-
dation of the PTP1B [123, 124] and of PTEN [125] and sup-
ported by the inhibition of its induction in the presence of
anti-oxidant scavengers [126]. Regarding the tumor cell
survival next to the hyperactivation of the PI3K/AKT and K-
ras signaling pathways the activation and stabilization of
Nrf2 is important for the protection of cancer cells from
oxidative stress.
Correlation of redox-sensitive proteins with
neoplastic transformation
H2O2-mediated signaling events have been reported to
affect major features of the cancer cell behavior. Since
H2O2 is involved in the regulation of apoptosis, cell cycle
progression and proliferation, the energy metabolism
and angiogenesis, specific redox-sensitive targets with
redox-sensor functions are necessary (Fig. 6, Table 2).
Redox control of the cellular energy metabolism with the
relation to cellular growth
In comparison to non-malignant normal cells, cancer cells
shift their metabolism to anaerobic glycolysis, which is
driven by multiple oncogenic pathways. The PI3K-driven
AKT activation leads to a direct regulation of glycolytic
enzymes and activation of mTOR. This has an effect on (i)
glycolytic enzymes by activation of HIF and/or (ii) induc-
tion of the glucose transporter GLUT1, enzymes of the
glycolysis as well as the mitochondrial PDK, which
inhibits the flux of pyruvate into the TCA [110] (Fig. 7).
AMPK can act as an energy sensor protein kinase and
opposes this effect by blocking the mTOR activity. There-
fore AMPK regulates the energy metabolism by activating
energy-producing pathways and inhibiting energy-
consuming processes in response to low intracellular ATP
levels thereby also linking cellular metabolism to growth
control and cell polarity [127]. This was further confirmed
by the AMPK inducer 5-aminoimidazole-4-carboxyamide
ribonucleoside, which inhibits tumor growth in vitro and
in vivo, suggesting that the AMPK signaling pathway
might contribute to the suppression of (tumor) growth by
acting as a metabolic checkpoint resulting in cell growth
arrest in the G1/S phase in the presence of low intracellu-
lar ATP levels [128–130]. Thus, AMPK has a strong im-
pact on the proliferation rate of both non-malignant as
well as tumor cells [131].
In addition to oncogenic mutations and signaling path-
ways [128] the AMPK activity can be suppressed by oxida-
tion of cysteine residues within the catalytic subunit alpha
at positions 130 and 174 promoting its aggregation. In
Fig. 6 Components of anti-oxidative systems involved in tumor development. Cancer cells are characterized by high levels of ROS (H2O2). To prevent
cell damage and cell death cancer cells induce the expression of anti-oxidative enzymes via the activation of the transcription factor Nrf2. Despite high
H2O2 levels cancer cells maintain the capacity to promote cell survival, differentiation and proliferation by undergoing metabolic adaption processes
thereby relying on the redox regulation of cancer-related redox sensors.
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contrast, the reduction of these sites is required for the
successful activation of the AMPK complex during energy
starvation, which is mediated by Trx thereby providing
evidence that oxidative stress and metabolism can be
linked via AMPK [132]. Furthermore, AMPK can function
as a sensor of genomic stress and interacts/enhances the
DNA damage response by interaction with the serine/
threonine protein kinase ATM [133] a redox sensor for
the regulation of DNA repair processes. Under physiologic
conditions ATM is recruited and activated by DNA
double-strand breaks (DSBs) via the formation of MRE11-
Rad50-Nibrin (MRN) DNA repair complexes. This results
in the phosphorylation of various key proteins involved in
DNA repair processes, such as p53, the serine/threonine-
protein kinase Chk2 (CHK2) and the histone H2AX
(H2AX) [134–137]. In the presence of H2O2 ATM forms
a disulfide-cross-linked dimer resulting in its direct activa-
tion independent from the MRN complex formation
thereby supporting its redox sensor function [138]. Fur-
thermore, ATM is involved in the regulation of mitochon-
drial function and metabolic control by interaction with
p53, AMPK, mTOR and HIF1α [139–141], which is inde-
pendent of DSBs [142]. In addition, the redox status of
tumors functions as a major determinant of the ATM-
dependent molecular switch of resistance to apoptosis. At
low ROS levels apoptosis was blocked, whereas increased
cellular ROS levels restored ATM/JNK-mediated apop-
totic signaling [143]. There is also evidence that patho-
logical neoangiogenesis requires ATM-mediated oxidative
defense, since agents promoting excessive ROS generation
have beneficial effects in the treatment of neovascular dis-
eases [144]. Not only AMPK, but also the pyruvate kinase
isoform M2 (PKM2), known to be over-expressed in tu-
mors [110], represents a switch between glycolysis and
gluconeogenesis. Inhibition of PKM2 caused by oxidative
modification of the cysteine residue at position 358 [145]
contributes to maintain cellular anti-oxidant responses by
diverting the glucose flux into the pentose phosphate
pathway thereby generating sufficient reducing potential
for the detoxification of ROS [146].
Redox control of cellular signaling processes in
association with angiogenesis and cell death
ROS, which are generated in response to various stimuli
including growth factors, have been shown to modulate
cellular growth and angiogenesis. A major source for
Table 2 Redox-sensitive proteins involved in the regulation of cell metabolism, angiogenesis and cell death
protein category modificationa cysteine residue effect
anti-oxidative defense-related redox sensors
Keap1 others S-S C151 inactivation [238]
2-cys Prx peroxidase sulfonic acid C51 inactivation [239]
Trx others S-S C32/C35 inactivation [240]
metabolism-related redox sensors
AMPK kinase G C299, C304 activation [241]
S-S C130, C174 inactivation [132]
ATM kinase S-S C2291 activation [138, 142]
PKM2 kinase C358 inactivation [146]
angiogenesis-related redox sensors
VEGFR receptor S-S C1206/C1199 inactivation [147, 148]
LMW-PTP phosphatase S-S C12/C17 inactivation [242]
SENP3 sumo C243 and/or C274 stabilization [158]
protease C243 HIF-1 transactivation [160, 161]
C532 inactivation, suppressed HIF-1 activity [160, 161]
Lyn kinase C466 recruitment of leukocytes [168, 169]
PKG kinase S-S C42 activation [172]
cell death-related redox sensors
ASK1 kinase S-S C250 inactivation [178, 179]
Fas receptor G C294 aggregation, FasL binding [186]
FOXO4 TF S-S C477 inactivation [189]
HMGB1 others S-S C23/C45 induction of apoptosis [193]
CFL others S-S, G C139/C147, C39/C80 inactivation, inhibition of apoptosis [208–210]
aC cysteine, S-S intra-/intermolecular disulfide, G glutathionylation
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ROS are NOX enzymes that can be activated by various
growth factors, e.g. vascular endothelial growth factor
(VEGF) and angiopoietin-1, leading to the induction of
genes involved in angiogenesis and thus represent thera-
peutic targets for the inhibition of tumor angiogenesis
[122]. H2O2 derived from NOX activities can affect the
vascular endothelial growth factor receptor (VEGFR) 2,
which regulates angiogenesis, vascular development, vas-
cular permeability and embryonic hematopoiesis, but
also promotes cell proliferation, survival, migration, and
differentiation of vascular endothelial cells. Despite
VEGFR1 and VEGFR2 can bind VEGFA, VEGFR2 plays
the major role in modulating these processes. Its activa-
tion depends not only on the autophosphorylation of de-
fined tyrosine residues, but is also regulated by oxidative
modifications [147, 148]. Increased cellular H2O2 levels
promote the formation of an intracellular disulfide bond
thereby blocking the receptor activity, whereas the
presence of Prx2 effectively prevents this oxidative modi-
fication leaving the receptor responsive to VEGFA
stimulation [147, 148]. Furthermore, extracellular H2O2
generated by extracellular SOD promotes VEGFR2 signal-
ing via oxidative inactivation of protein tyrosine phospha-
tases (PTPs) in mice [149]. Moreover, the expression of
TXNIP is required for the VEGF-mediated VEGFR2 acti-
vation and angiogenic response in vivo and in vitro by
regulating VEGFR2 phosphorylation via S-glutathionyla-
tion of the low molecular weight protein tyrosine phos-
phatase (LMW-PTP) in endothelial cells [150]. In addition
the interaction of TXNIP with the poly-ADP-ribose poly-
merase 1 (PARP1) is a relevant regulator for its transloca-
lization and function leading to the activation of VEFGR2
signaling in human umbilical vein endothelial cells [151].
Furthermore, H2O2 was shown to induce the expression
levels of the VEGFR2 ligand VEGF by inducing the tran-
scription factors NFκB or AP-1 [152]. Under hypoxic con-
ditions VEGF expression is upregulated by HIF1α which is
over-expressed in many tumors and its activity levels
influence angiogenesis as well as tumorigenesis
[153]. Under normoxic conditions HIF1α is hydroxylated
Fig. 7 Redox control of the cellular energy metabolism. In cancer cells the shift of the metabolism into anaerobic glycolysis is mainly mediated by the
PI3K/AKT pathway. AKT activates mTOR, which subsequently activates HIF1α resulting in an induction of GLUT1, enzymes of the glycolysis and the
mitochondrial PDK, which inhibits the pyruvate flux into the TCA. The AMPK is able to block this mechanism by inhibition of mTOR to conserve energy.
Cancer cells exhibit high ROS (H2O2) levels leading to an inhibition of the AMPK and of PTPs, which can inactivate AKT. Even through high H2O2 levels
DSBs could occur leading to the activation of ATM accompanied with cell cycle arrest. The interaction of ATM and AMPK might enhance the DNA
damage response. In addition H2O2 might inactivate the PKM2 leading to an altered flux of glucose in the pentose phosphate pathway
for the generation of reductions equivalents to detoxify ROS. PDK, pyruvate dehydrogenase kinase; PKM2, pyruvate kinase M2; TCA,
tricarboxylic acid.
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and subsequently ubiquitinated for proteasomal degrad-
ation, whereas under hypoxic conditions its hydroxylation
is blocked leading to its accumulation, dimerization with
its beta subunit and subsequent translocation into the nu-
cleus, where it regulates the expression of genes linked to
cellular transformation, cell proliferation and angiogenesis
[154–156]. The transcriptional activity of HIF1α depends
on the translocation of sentrin/SUMO-specific protease 3
(SENP3) from the nucleoli to the nucleoplasm [157]. ROS
seem to be involved in limiting its proteasomal degrad-
ation. The complex formation with either the heat shock
protein 90 (Hsp90) or the co-chaperone/ubiquitin ligase
carboxyl terminus of Hsc70-interacting protein (CHIP)
leads to the stabilization or degradation of SENP3. Under
mild oxidative stress the oxidation of thiol residues favors
the recruitment of Hsp90 thereby protecting SENP3 from
binding to CHIP, which results in its ubiquitination and
subsequent elimination via proteasomal degradation.
Thus, the redox status of SENP3 is a decisive factor for its
stabilization or degradation [158] and can regulate the ex-
pression of the EMT-inducing transcription factor fork
head box C2 (FOXC2) that is de-SUMOylated and thereby
activated in response to increased ROS levels. As a result
the expression of the mesenchymal marker protein N-
cadherin is induced [159]. In HeLa cells ROS levels are in-
volved in the activation of HIF1α by modifying cysteine
residues at positions 243 and 532 of SENP3 thereby con-
trolling the interaction of SENP3 with p300, the co-
activator of HIF1α. This is accompanied by SUMOylation
of p300 resulting in the transcriptional silencing of HIF1α.
The shift of HIF1α transactivation by ROS depends on the
biphasic redox sensing of SENP3. Whereas low ROS levels
lead to SENP3 accumulation and therefore enhanced
HIF1α transcriptional activity, high concentrations of ROS
inactivated SENP3 resulting in the suppression of HIF1α
transcriptional activity. Thus SENP3 is an example for a
redox sensitive protein with cysteine residues that can
sense different ROS levels [160, 161]. VEGF can also pro-
mote endothelial permeability through the activation of
the Src family non-receptor tyrosine kinases (SFKs) [162].
Lyn, a member of the SFK family, has been shown to be
amplified and upregulated in tumor cells, which is associ-
ated with resistance to chemotherapy [163] and plays an
important role in the regulation of both innate and adaptive
anti-tumoral immune responses. Since NOX-expressing tu-
mors are able to efficiently produce H2O2, the tumor
stroma can mimic features of ‘unhealed’ wounds [164].
Using distinct model systems, extracellular H2O2 levels
have been linked to the recruitment of leukocytes, such as
neutrophils, representing the first line of innate immune
responses [165–167]. In addition, Lyn serves as a redox
sensor for neutrophils monitoring the redox state of
wounds. The oxidation-specific modification site was
defined as cysteine residue 466, which directly triggered the
wound response and calcium signaling [168, 169]. In re-
sponse to treatment with chromium (V) complexes the for-
mation of ROS and activation of Lyn were found in
lymphocytes leading to the activation of caspase-3 and sub-
sequently to the induction of apoptosis [170]. Another kin-
ase with redox-sensor function and involvement in
angiogenesis is the cGMP-dependent protein kinase (PKG).
PKG represents a member of a serine/threonine-specific
protein kinase family that acts as a key mediator of the ni-
tric oxide (NO)/cGMP signaling pathway. GMP binding
has been shown to activate PKG resulting in the phosphor-
ylation of serine and threonine residues on many cellular
proteins [171] involved in modulating cellular calcium. Be-
sides this activation mechanism it is also known that PKG
can be activated under oxidative stress independent of the
respective cGMP or NO levels [172]. PKG controls the
regulation of platelet activation and adhesion, smooth
muscle contraction, cardiac function, gene expression and
the feedback of the NO-signaling pathway amongst others.
While the expression of PKG in metastatic colon carcin-
oma blocks tumor angiogenesis by down-regulating the ex-
pression level of beta-catenin [173], PKG signaling can also
mediate cytoprotective and anti-apoptotic function in vari-
ous tissues including non-small-cell lung carcinoma. Thus,
PKG inhibitors might be of therapeutic relevance and have
been suggest for treatment in combination with cisplatin
chemotherapy of solid tumors [174]. PKG-inhibitors limit
the migration and invasion capacity of colorectal carcinoma
cells [175]. Moreover, pro-apoptotic effects of PKG signal-
ing have been reported for various colon carcinoma as well
as breast cancer cell lines, which is in line with the hypoth-
esis that the loss of PKG expression in colon carcinoma cell
lines may contribute their resistance to undergo anoikis
[176, 177].
Redox control of cellular signaling processes in association
with apoptosis
By acting as a mitogen-activated protein (MAP) kinase
kinase kinase (MAPKKK) ASK1 can activate two dis-
tinct sets of MAPKK. Whereas the tumor necrosis
factor alpha (TNF-α)-mediated activation of MKK4
(SEK1) via its downstream target JNK leads to the in-
duction of apoptotic cell death, the activation of MKK6
activates p38 subgroups of MAPK, which phosphorylate
a wide range of potential targets in response to inflam-
matory cytokines and cellular stress. A key role in the
ASK1-mediated induction of apoptosis via MKK is its
dimer formation, known to be induced by exposure to
H2O2, but blocked by Trx supporting its role as a redox
sensor. Moreover, the interaction of ASK1 and Trx is
based on the formation of a disulfide bond at the N-
terminal domain of ASK1 leading to its ubiquitination
and subsequent proteasomal degradation. However,
high levels of H2O2 caused a loss of the protective
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function of Trx due to the formation of an intramo-
lecular disulfide bond resulting in its release from
ASK1, which is accompanied by its activation [178,
179]. Furthermore, the selective inhibition of TrxR by
the drug MC3 or by electrophilic pollutants leads to
the induction of apoptosis via the Trx-ASK1-p39 signal
cascade by blocking the interaction of Trx with ASK1
[180, 181]. In addition, redox alterations induced by se-
lective inhibition of the glucose metabolism leading to
massive oxidative stress might serve as a molecular
switch that activates the ASK1-JNK/p38 MAPK signal-
ing pathways accompanied by promotion of the radio-
sensitization of malignant cells [182]. Similar effects
have been reported in response to treatment with iron
chelators, which also resulted in reduced ASK1-Trx
complex formation [183]. The genetic inhibition of
ASK1 resulted not only in the inhibition of JNK activa-
tion, but also in decreased expression of Fas ligand
(FasL) and subsequent apoptosis, whereas the inhibition
of p38 did not alter the FasL expression [184]. The acti-
vation of Fas upon ligand engagement leads to the forma-
tion of a death-inducing signaling complex accompanied
by caspase 8-mediated apoptosis [185]. The Fas/FasL
interaction results in the S-glutathionylation of Fas at cyst-
eine residue 294 [186], which not only increases the bind-
ing to its ligand, but also its aggregation and recruitment
into lipid rafts. This oxidative modification can be linked
to the activity of Grx1 [187], since the depletion of Grx1
results in an increased S-glutathionylation rate along with
the induction of apoptosis, while Grx1 overexpression
causes opposite effects. The level of oxidative stress medi-
ated by exogenous sources or endogenously generated
upon receptor stimulation regulates the sensitivity to Fas-
mediated apoptosis [188]. Additionally FOXO4, a TF in-
volved in the regulation of the insulin signaling pathway,
can be activated by oxidative stress due to the formation
of an intermolecular disulfide bond between cysteine resi-
due 477 and histone acetyltransferase p300 resulting in
the formation of a covalently linked heterodimer. The
redox modification of FOXO4 is essential for its subse-
quent CREB-binding protein (CBP)-mediated acetylation
[189]. However, the activity of the heterodimeric complex
is regulated by the Trx system, which has a strong impact
on the turnover of this interaction by reducing the
cysteine-dependent heterodimer of FOXO4 and p300
thereby providing evidence that Trx might be a key regula-
tor of ROS-dependent FOXO4 signaling [189]. In addition,
the efficient nuclear translocation and subsequent activa-
tion of FOXO4 in response to ROS depends on disulfide
formation with the nuclear import receptor transportin-1
(TNPO1), whereas its insulin signaling-dependent nuclear
shuttling is not dependent on TNPO1 [190]. Although
high-mobility group box 1 protein (HMGB1) might act as a
redox-sensitive switch between autophagy and apoptosis.
HMGB1 is a DNA-binding protein that associates with
chromatin, but can also bind single stranded DNA linking
the assembly of transcriptional active protein complexes on
specific targets. Its reduced form interacts with the receptor
for advanced glycation end products (RAGE) thereby indu-
cing beclin1-dependent autophagy [191]. In the presence of
higher ROS levels HMGB1 can undergo oxidative modifi-
cation leading to the formation of a disulfide bond between
cysteine residues 23 and 45 [192], which induces apoptosis
via the intrinsic pathway [193]. When released in its par-
tially oxidized status, HMGB1 functions as a pro-
inflammatory cytokine [194], whereas in its fully oxidized
form (sulfonylated) all biologic activities are lost. Further-
more, HMGB1 can be released from both activated and
dying cells thereby acting as a damage-associated molecular
pattern molecule [195]. However, its biochemical and im-
munological properties depend on both its cellular
localization as well as its release mechanism [196]. Due to
different intracellular and extracellular functions HMGB1 is
a central mediator in inflammation and immunity, but its
activity depends on the state of its redox-sensitive cysteine
residues at positions 23, 45 and 106 ranging from DNA
binding, to induction of chemotaxis and transcription of
chemokines [197, 198] suggesting its classification as an
“alarmin” for sepsis and cancer [199]. Different diseases,
such as cancer, are often accompanied by T cell hypore-
sponsiveness, which is mediated by ROS. The release of
H2O2 produced by tumor-infiltrating macrophages leads to
the suppression of potentially tumor reactive T cells [200].
Cofilin (CFL), a member of the actin-depolymerizing factor
protein family, binds to F-actin and plays an important role
in the regulation of the actin cytoskeleton dynamics as well
as in the mitochondrial apoptosis. Its translocation from
the cytoplasm into the mitochondria leads to cytochrome c
release and activation of caspase signaling, thus represent-
ing an early step in the induction of apoptosis [201, 202].
Since CFL is also associated with invasion and metastatic
capacity of tumors [203–206], it is a key therapeutic target
for tumors [207]. CFL might function as a redox sensor
[208] and its dephosphorylation-dependent glutathionyla-
tion [209, 210] not only leads to a loss of its actin binding
affinity, but also blocks its translocation to the mitochondria
thereby preventing apoptosis induction. The oxidation-
mediated inactivation of CFL can also provoke Tcell hypore-
sponsiveness or the necrotic-like programmed cell death,
which modulates the T cell activation processes including
the duration of the effectors phase [211]. In contrast, knock-
down of CFL could protect T cells from fatal effects of long-
term oxidative stress [212] suggesting that oxidation and
mitochondrial localization of CFL represents a check point
for necrotic-like cell death. Therefore the oxidation of CFL
might provide a molecular explanation for the T cell hypore-
sponsiveness found in diseases such as cancer under oxida-
tive stress conditions [200].
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Components of redox regulating processes as
therapeutic targets
Tumor cells take the advantage of upregulating anti-
oxidant systems to protect themselves against ROS-
induced cell damage. The upregulation of anti-oxidant
molecules is often associated with an increased cell pro-
liferation, survival and chemotherapy resistance. There-
fore components of the anti-oxidant processes including
the Trx system represent potential therapeutic targets
for the treatment of cancer patients to trigger ROS me-
diated cell death (Table 3). This is in line with the re-
duced tumor cell proliferation, induced apoptosis and
increased sensitivity of tumor cells to anti-cancer therapy
in the presence of Trx and TrxR1 inhibitors [213, 214].
Since a cross-talk between different anti-oxidant molecules
has been shown, a combinatorial targeting of these mole-
cules is essential for complete inhibition of the anti-oxidant
defense system. Indeed inhibition of TrxR in combination
with the disruption of the GSH biosynthesis, caused a se-
lective cell death of human head, neck, and lung cancer
cells by inducing oxidative stress [215, 216]. In addition to
targeting the Trx system other molecules, e.g. the inhibition
of the PTEN axis [217] or the protein deglycase DJ-1 (DJ-1)
known to exhibit anti-oxidative and cyto-protective func-
tions in other diseases [218–220] might have therapeutic
potential, since DJ-1 is often upregulated in cancer cells
and involved in the regulation of various redox stress re-
sponsive signaling pathways (PI3K/AKT/PKB; Trx1/ASK1)
[217, 221]. Thus, a combined targeting of Trx and DJ-1 re-
sult in a complete loss of the anti-oxidant defense system
[217].
However, the interaction between different anti-
oxidant molecules in distinct tumor models requests fur-
ther analysis to increase the insights of the underlying
molecular mechanisms of these interactions and the
identification of additional molecular targets for cancer
therapy. In addition, a better understanding of the role
of the intracellular redox state balance and the redox-
regulated signaling cascades might enhance the thera-
peutic options for the treatment of various human
cancer types.
Conclusions
Many cancer cells are characterized by an increased in-
trinsic formation of ROS as a result of their malignant
transformation process. Yet, they have to adapt to this
challenge in order to maintain the capacity for tumor pro-
gression. ROS, in particular H2O2, play an important role
in facilitating both cell proliferation and cell survival of
tumor cells by triggering the redox signaling cascades.
New therapeutic approaches are currently developed that
aim towards altering the tumor cell redox state, including
(i) the selective inhibition of cellular ROS sources [222, 223],
e.g. NOX, (ii) the hyperactivation of anti-oxidant enzymes to
lower intracellular ROS levels and (iii) the modulation of the
anti-oxidant response system towards increasing ROS levels
thereby further promoting the induction of apoptosis. So far,
the underlying molecular mechanisms of the interactions be-
tween different redox signaling compounds and the tumor
progression processes are not fully understood. In addition,
there is still a need to define additional redox sensors. There-
fore, further research is required to gain additional insights
into these signaling networks and sensors, which then might
lead to the identification and subsequent design of novel tar-
geted therapies for the treatment of cancer patients.
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Table 3 Current therapeutic strategies for the treatment of
cancer patients to trigger ROS-mediated cell death
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biosynthesis
head and neck cancer cells,
malignant B cells [215, 216]
+ Selenocystin lung cancer [214]
MJ25 TrxR inhibitor melanoma [213]
Imexon prooxidant, cysteine
depletion
B cell non-Hodgkin lymphoma
[243, 244]
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